Alexander Gottschalk

Alex Gottschalk

Alexander R. Gottschalk, M.D., Ph.D.

Professor and Vice-Chair

Department of Radiation Oncology

University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
Box 1708,1600 Divisadero St, H1031
San Francisco, CA 94115
Phone: 415 353-7175
Fax 415 353-9883

Make A Gift Button

Professional Focus

Dr. Gottschalk is involved in a number of clinical research projects. First, he has studied several methods of image-guided radiotherapy (IGRT), including ultrasound, electronic portal imagining using gold seed fiducial markers and megavoltage cone-beam CT (MVCBCT). His research is one of the first to evaluate prostate bed motion in patients undergoing radiotherapy after prostatectomy. Dr. Gottschalk has investigated the use of MVCBCT for dose calculation and re-calculation as well as a novel high quality, low dose, imaging beam line. The dose re-calculation can be used for dose guided radiation therapy (DGRT). Second, using the Radiation Oncology clinical database, Dr. Gottschalk has studied: the effectiveness of intraoperative radiation therapy (IORT) in the management of extremity sarcomas and renal cell carcinoma recurrences, permanent seed brachytherapy and high dose-rate brachytherapy (HDR) for the treatment of prostate cancer both as primary therapy and as salvage after radiation failures. Third, he has been involved as a co-investigator in three trials: a phase II, single-center, open-label phase I/II study to evaluate efficacy and safety in patients who have resectable esophageal cancer and are treated with neoadjuvant cisplatin, irinotecan (CPT-11), ZD1839 (IRESSA®), and radiotherapy followed by surgical resection; a phase II study of radiation therapy, paclitaxel poliglumex and carboplatin in stage III non-small cell lung cancer; and a phase I/II open-label dose escalation study of anti-CTLA4 antibody with radiation for metastatic hormone refractory prostate cancer. Fourth, Dr. Gottschalk is involved with several RTOG (Radiation Therapy Oncology Group) studies. These have included several prostate cancer trials that investigate: high-dose vs standard-dose radiation for intermediate-risk prostate cancer; brachytherapy vs external-beam radiation plus brachytherapy for intermediate-risk prostate cancer; and standard fractionation vs hypofractionation for low-risk prostate cancer. Finally, as Director of the CyberKnife Radiosurgery Program Dr. Gottschalk oversees several of the stereotactic body radiosugery (SBRT) trials for lung and prostate cancer. He has a particular interest in the use of CyberKnife SBRT for the treatment of prostate cancer, kidney cancer, and lung cancer.

Education

1988 University of Chicago BA Chemistry
1994 University of Chicago PhD Pathology
1996 University of Chicago MD Medicine
1996-1997 Kaiser Permanente Medical Center, Santa Clara, CA Intern Internal Medicine
1997-2001 UCSF Resident Radiation Oncology
01/00-04/00 UCSF Chief Resident Radiation Oncology

 

Professional Experience

2008-Present UCSF Director of the CyberKnife Radiosurgery Program
2008-Present UCSF Associate Professor
2007-2008 UCSF Interim Director of the CyberKnife Radiosurgery Program
2001-2008 UCSF Assistant Professor
1997-2001 UCSF Residency in Radiation Oncology
1996-1997 Kaiser Internal Medicine Internship

 

Awards & Honors

1984-1988 Dean's List; National Science Foundation Fellowship for undergraduate research in Chemistry; National Science Foundation Graduate Fellowship, Honorable Mention; Phi Beta Kappa; B.A. with General Honors
1988-1992 NIH Medical Scientist Training Program Fellowship, University of Chicago, Chicago, IL
1992-1994 NIH Training Grant, Department of Molecular Genetic & Cell Biology, University of Chicago, Chicago, IL
1994-1996 Medical Scientist Training Program Fellowship, University of Chicago, Chicago, IL
1998-1999 NIH National Research Service Award, Department of Radiation Oncology, University of California San Francisco
2000 RSNA Research & Education Foundation Roentgen Resident/Fellow Research Award
2001-2002 Clinical Investigator Research Program Recipient, University of California San Francisco
2002 Invited speaker at the Radiation Oncology Young Investigator's Symposium, Bethesda, MD
2002-2003 UCSF Prostate Cancer SPORE Developmental Research Program Award
2002-2003 Co-investigator on UCSF Prostate Cancer SPORE, Project 3
2003-2005 RSNA Research Scholar Award
2003-2005 ASTRO Junior Faculty Award

 

Recent Significant Publications :

Chen CP, Weinberg V, Shinohara K, Roach M 3rd, Nash M, Gottschalk A, Chang AJ, Hsu IC. Salvage HDR Brachytherapy for Recurrent Prostate Cancer After Previous Definitive Radiation Therapy: 5-Year Outcomes. Int J Radiat Oncol Biol Phys. 2013 Mar 5.

Hsu CC, Hsu H, Pickett B, Crehange G, Hsu IC, Dea R, Weinberg V, Gottschalk AR, Kurhanewicz J, Shinohara K, Roach M 3rd. Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer. Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):370-7.

Jabbari S, Weinberg VK, Kaprealian T, Hsu IC, Ma L, Chuang C, Descovich M, Shiao S, Shinohara K, Roach M 3rd, Gottschalk AR. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response. Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):228-34.

Kaprealian T, Weinberg V, Speight JL, Gottschalk AR, Roach M 3rd, Shinohara K, Hsu IC. High-dose-rate brachytherapy boost for prostate cancer: comparison of two different fractionation schemes. Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):222-7.

Shiao SL, Sahgal A, Hu W, Jabbari S, Chuang C, Descovich M, Hsu IC, Gottschalk AR, Roach M 3rd, Ma L. Temporal compartmental dosing effects for robotic prostate stereotactic body radiotherapy. Phys Med Biol. 2011 Dec 21;56(24):7767-75.

Faddegon BA, Aubin M, Bani-Hashemi A, Gangadharan B, Gottschalk AR, Morin O, Sawkey D, Wu V, Yom SS. Comparison of patient megavoltage cone beam CT images acquired with an unflattened beam from a carbon target and a flattened treatment beam. Med Phys. 2010 Apr;37(4):1737-41.

Hossain S, Xia P, Huang K, Descovich M, Chuang C, Gottschalk AR, Roach M 3rd, Ma L. Dose gradient near target-normal structure interface for nonisocentric CyberKnife and isocentric intensity-modulated body radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):58-63.

Aubry JF, Jabbari S, Hsu IC, Kawakami J, Weinberg VK, Speight JL, Gottschalk AR, Roach M 3rd, Shinohara K. High-dose-rate brachytherapy for localized prostate adenocarcinoma post abdominoperineal resection of the rectum and pelvic irradiation: Technique and experience. Brachytherapy. 2009 Oct-Dec;8(4):339-44.

Aubry JF, Cheung J, Morin O, Gottschalk A, Beaulieu L, Pouliot J. Correction of megavoltage cone-beam CT images of the pelvic region based on phantom measurements for dose calculation purposes. PMID 19223832 Journal of Applied Clinical Medical Physics 10(1):2852, 2009.

Aaronson DS, Yamasaki I, Gottschalk A, Speight J, Hsu IC, Pickett B, Roach M, and Shinohara K. Salvage permanent perineal radioactive seed implantation for the treatment of localized prostate adenocarcinoma recurrent after external beam radiation. PMID: 19245439 British Journal Urology International, February 23, 2009.